Samsung Bioepis execs arrested, reports say

30 April 2019
samsung-bioepisbig

An executive and another employee at Korean biosimilars powerhouse Samsung Bioepis have been arrested, according to The Financial Times and other sources.

The report states that the pair are suspected of destroying evidence to cover up an alleged 4.5 trillion won ($3.9 billion) accounting fraud, and have been arrested as part of an investigation into the case that was launched last year.

Samsung Bioepis is a joint venture involving the US biotech company Biogen (Nasdaq: BIIB) and Samsung BioLogics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars